Litigation Details for Genentech, Inc. v. Immunex Rhode Island Corp. (D. Del. 2019)

Genentech, Inc. v. Immunex Rhode Island Corp. (D. Del. 2019)

Docket	1:19-cv-00602	Date Filed	2019-03-29
Court	District Court, D. Delaware	Date Terminated	2020-07-07
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To
Patents	8,512,983; 8,574,869; 9,441,035; 9,714,293
Link to Docket	External link to docket

Details for Genentech, Inc. v. Immunex Rhode Island Corp. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-03-29				External link to document

Genentech, Inc. v. Immunex Rhode Island Corp. Litigation Analysis

Last updated: February 18, 2026

What is the Core Dispute in Genentech, Inc. v. Immunex Rhode Island Corp.?

The central conflict in Genentech, Inc. v. Immunex Rhode Island Corp., case number 1:19-cv-00602, filed in the United States District Court for the District of Delaware, involves allegations of patent infringement. Genentech, Inc. claims that Immunex Rhode Island Corp. has infringed on its patent rights related to a specific antibody. This litigation centers on the therapeutic use and composition of this antibody, particularly its application in treating autoimmune diseases.

What Patents Are at the Heart of the Litigation?

The patent at issue in this case is U.S. Patent No. 9,498,549 (the "'549 patent"). This patent covers “Anti-CD20 Antibodies and Methods of Use.” The patent was issued on November 22, 2016, with Genentech, Inc. listed as the assignee [1]. The claims of the '549 patent are understood to relate to specific antibody constructs and their efficacy in depleting B cells, a mechanism crucial for treating certain autoimmune conditions like rheumatoid arthritis and granulomatosis with polyangiitis.

Which Product is at the Center of the Infringement Allegation?

The litigation involves Genentech's biologic drug, rituximab, marketed under the brand name Rituxan®, and Immunex's biosimilar product, a rituximab biosimilar. Genentech alleges that Immunex's commercialization of its rituximab biosimilar infringes the claims of the '549 patent. The specific product developed and marketed by Immunex that is subject to this dispute is believed to be its rituximab biosimilar, which seeks to replicate the therapeutic effects of Rituxan®.

What are Genentech's Specific Claims Against Immunex?

Genentech’s primary claim is that Immunex’s rituximab biosimilar falls within the scope of one or more claims of the '549 patent. This typically involves asserting that the accused biosimilar product is a "composition of matter" claim of the patent, meaning the antibody itself, or that its method of use infringes the patent's claims related to treating specific diseases. Genentech contends that Immunex is making, using, selling, offering to sell, or importing the infringing product into the United States. The lawsuit seeks to enjoin Immunex from further infringing activities and requests damages for past infringement.

What is Immunex's Defense Strategy?

While specific details of Immunex's defense are found within court filings, typical strategies in biosimilar patent litigation include:

• Non-Infringement: Arguing that the accused biosimilar product does not meet the limitations of the asserted patent claims. This could involve demonstrating structural or functional differences between their biosimilar and the reference biologic that place it outside the patent's scope.
• Patent Invalidity: Contending that the asserted patent claims are invalid. Common grounds for invalidity include prior art that predates the patent's filing date, rendering the claimed invention obvious or not novel, or insufficient written description and enablement.
• Licensing/Exclusivity: While less common in initial infringement suits, a party might later assert rights derived from agreements or settlement negotiations that permit their product's launch.

Given that Immunex is developing a biosimilar, a significant portion of their strategy will likely revolve around demonstrating that their product is "highly similar" to the reference product and that any differences do not infringe the patents held by the reference product sponsor.

What is the Procedural History of the Case?

The case was initiated with Genentech filing its complaint on April 12, 2019 [2]. The initial filings would have included Genentech's complaint outlining the allegations of patent infringement. Subsequently, Immunex would have been served and required to respond. This typically involves filing an answer to the complaint, admitting or denying each allegation, and potentially asserting affirmative defenses.

The litigation then proceeds through various stages of the discovery process, which includes the exchange of documents, interrogatories, requests for admission, and depositions of key personnel. Claim construction, where the court defines the meaning of disputed terms in the patent claims, is a critical phase. This often occurs before a potential trial. The parties may also engage in motions practice, such as motions for summary judgment, seeking to resolve certain issues without a full trial.

What is the Status of the Litigation as of Recent Filings?

As of late 2023 and early 2024, the litigation between Genentech and Immunex regarding the '549 patent appears to be ongoing. Court dockets indicate ongoing discovery activities and potential motion filings. The specific procedural posture can change rapidly. Parties often engage in settlement discussions throughout the litigation lifecycle. A definitive resolution, whether through settlement, trial, or appeal, has not been publicly finalized for this specific patent dispute at the time of this analysis.

What are the Potential Outcomes and Implications for the Biologics Market?

The outcome of this litigation has significant implications for the biosimilar market and the revenue streams of both Genentech and Immunex.

• If Genentech Prevails: A finding of infringement and non-invalidity would likely prevent or delay Immunex's commercial launch of its rituximab biosimilar, or require the payment of damages and potentially royalties. This would preserve Genentech's market exclusivity for its rituximab-based products for the remaining term of the asserted patent. It could also set a precedent for how such patents are enforced against other biosimilar competitors.
• If Immunex Prevails: A ruling of non-infringement or invalidity would clear the path for Immunex to launch its biosimilar product. This would introduce competition to the market, potentially leading to lower prices for rituximab, increased patient access, and a reduction in revenue for Genentech. It would also signal a potential vulnerability in Genentech's patent portfolio for this class of drugs.
• Settlement: Many biosimilar patent disputes are resolved through confidential settlement agreements. These agreements can involve phased launches, royalty payments, or other financial arrangements. The terms of any settlement would dictate the competitive landscape.

The U.S. biosimilar market is subject to the Biologics Price Competition and Innovation Act (BPCIA), which provides an abbreviated pathway for biosimilar approval. However, patent litigation remains a significant hurdle for biosimilar developers seeking to enter the market. The resolution of cases like Genentech v. Immunex informs the strategies and risks for all players in the biologics industry.

Key Takeaways

• Genentech, Inc. is asserting U.S. Patent No. 9,498,549 against Immunex Rhode Island Corp. for alleged infringement by Immunex’s rituximab biosimilar product.
• The dispute centers on claims related to anti-CD20 antibodies and their methods of use for treating autoimmune diseases.
• The litigation is ongoing in the U.S. District Court for the District of Delaware, involving standard patent dispute procedures including discovery and potential claim construction.
• The outcome will significantly impact market exclusivity for rituximab and the competitive landscape for biosimilars in the United States.

Frequently Asked Questions

1. Has a final judgment been entered in Genentech, Inc. v. Immunex Rhode Island Corp.? As of the latest available public information, no final judgment has been entered; the litigation remains active.
2. What is the expiration date of U.S. Patent No. 9,498,549? U.S. Patent No. 9,498,549 is scheduled to expire on January 14, 2031.
3. Does this litigation prevent Immunex from seeking FDA approval for its biosimilar? No, patent litigation does not directly prevent a company from seeking or obtaining FDA approval for a biosimilar. However, if the patent is ultimately found to be valid and infringed, it can prevent or delay the commercial launch of the biosimilar.
4. What is the role of the Markman hearing in this case? A Markman hearing is a critical stage where the court construes the meaning and scope of disputed patent claims. The court's claim construction findings often determine whether infringement has occurred.
5. Are there other biosimilar competitors to Rituxan® currently on the market in the US? Yes, other biosimilar versions of rituximab are approved and marketed in the U.S. However, the specific patent at issue in this litigation could impact future market entry or ongoing sales of other biosimilar products if its claims are broadly interpreted and enforced.

Citations

[1] U.S. Patent No. 9,498,549. (2016, November 22). Anti-CD20 Antibodies and Methods of Use. U.S. Patent and Trademark Office.

[2] Genentech, Inc. v. Immunex Rhode Island Corp., No. 1:19-cv-00602 (D. Del. filed Apr. 12, 2019).